)
)
Calliditas Therapeutics Investor Relations Material
Latest events
Q2 2024
Calliditas Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Calliditas Therapeutics
Access all reports
Segment Data
Access more data
Net sales by
Geography
U.S.
Asia
Europe
Expenses by
Financials
Calliditas Therapeutics AB, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. Its lead product candidate is Nefecon that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy. Calliditas Therapeutics AB was founded in 2004 and is headquartered in Stockholm, Sweden.
Key slides for Calliditas Therapeutics
Q4 2023
Calliditas Therapeutics
Q2 2024
Calliditas Therapeutics
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
CALTX
Country
🇸🇪 Sweden